Showing results (31-40 of 85) with videos related to
Sort By:
Pageof 9
Ebiomedicine|August 15, 2019
Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanomaRobert H I Andtbacka, Thomas Amatruda, John Nemunaitis, et al.Cancer|February 23, 2018
Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trialsKaren Kelly, Jeffrey R Infante, Matthew H Taylor, et al.Investigational New Drugs|August 8, 2019
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumorsMark N Stein, Susan Goodin, Murugeson Gounder, et al.Journal for Immunotherapy of Cancer|October 16, 2014
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case seriesSowmya Ravi, Kristen Spencer, Mary Ruisi, et al.Frontiers in Oncology|February 27, 2023
A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanomaAnn W Silk, Brendan Curti, Jennifer Bryan, et al.Journal for Immunotherapy of Cancer|October 6, 2020
Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancerShang-Jui Wang, Karishma Khullar, Sinae Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2017
<i>BRAF</i> Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in <i>BRAF</i><sup>V600E</sup> Mutant MelanomaAtul Kulkarni, Husam Al-Hraishawi, Srilatha Simhadri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2017
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 StudyChiun Hsu, Se-Hoon Lee, Samuel Ejadi, et al.Journal for Immunotherapy of Cancer|January 18, 2019
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trialUlrich Keilholz, Janice M Mehnert, Sebastian Bauer, et al.European Journal of Medical Research|July 2, 2022
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumorsAnn W Silk, Biren Saraiya, Roman Groisberg, et al.Pageof 9